IMN || FDA & CDC

FDA approves PARP-inhibitor for ovarian cancer

Posted on: 19/12/2014 - 18:41

Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has been approved for treating advanced ovarian cancer associated with defective BRCA genes, the Food and Drug Administration announced on...

Field of Interest: Pulmonology
Type: News Item

FDA approves PARP-inhibitor for ovarian cancer

Posted on: 19/12/2014 - 18:41

Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has been approved for treating advanced ovarian cancer associated with defective BRCA genes, the Food and Drug Administration announced on...

Field of Interest: Oncology
Type: News Item

Abortion rates reach historic low in 2011

Posted on: 02/12/2014 - 17:04

The total number of abortions, the rate of abortions per 1,000 women, and the ratio of abortions to live births all reached historic lows in 2011, according to a study published in Morbidity and...

Field of Interest: Pulmonology
Type: News Item

Veterans more likely to have arthritis at any age

Posted on: 12/11/2014 - 16:35

Both male and female veterans were more likely to have arthritis than were nonveterans, according to a study from the Centers for Disease Control and Prevention. For male veterans, the...

Field of Interest: Rheumatology
Type: News Item

CDC: More can be done to prevent cervical cancer fatalities

Posted on: 05/11/2014 - 19:54

Close to 8 million women aged 21-65 years were not screened for cervical cancer in the past 5 years even though the disease claims nearly 4,000 lives per year, according to 2012 data, the Centers for...

Field of Interest: Oncology
Type: News Item

FDA approves hepatitis C combination pill

Posted on: 11/10/2014 - 16:34

The first combination pill to treat chronic hepatitis C virus genotype 1 infection was approved by the Food and Drug Administration Oct. 10. The once-daily tablet under the trade name Harvoni...

Field of Interest: Gastroentero...
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness